Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen

Joaquin Burgos, Manuel Crespo, Vicenç Falcó, Adria Curran, Arkaitz Imaz, Pere Domingo, Daniel Podzamczer, Maria Gracia Mateo, Eva Van den eynde, Sara Villar, Esteve Ribera

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Objectives: To assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen. Methods: Retrospective analysis of 60 consecutive HIV-1-infected patients who started a dual-antiretroviral rescue regimen containing a PI/r, in three hospitals in Spain. Virological failure was defined as confirmed HIV RNA >50 copies/mL at treatment week 24 or later. The percentage of patients remaining free of therapeutic failure was estimated using the Kaplan-Meier method, by intent-to-treat analysis (missing, changes and virological failure=therapeutic failure). Results: Median baseline characteristics of patients were: 13 years on antiretroviral therapy (four prior highly active antiretroviral therapy regimens and eight different drugs), 380 CD4 cells/mm. 3 and HIV RNA 3.04 log. 10 copies/mL. All patients had resistance mutations to at least two drug classes, although only 9.3% had specific mutations to darunavir. A darunavir-based regimen was started in 47 (78.4%) patients, combined with etravirine (26.7%), tenofovir (26.7%) or raltegravir (25%). Three (5%) patients discontinued treatment due to side effects. At the end of follow-up, 86.7% of patients remained free of therapeutic failure; the percentages of patients with no therapeutic failure at treatment weeks 24, 48 and 96 were 96.6% (95% CI, 91.9-101.3); 90.1% (95% CI, 81.9-98.3) and 79.8% (95% CI, 66.1-93.5), respectively. Conclusions: Our results suggest that a dual-therapy rescue regimen including a PI/r is convenient, well tolerated and potent enough to achieve persistent viral suppression in selected pre-treated patients with low viral load and few PI resistance mutations. © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Original languageEnglish
Article numberdks057
Pages (from-to)1453-1458
JournalJournal of Antimicrobial Chemotherapy
Volume67
Issue number6
DOIs
Publication statusPublished - 1 Jun 2012

Keywords

  • Dual-antiretroviral therapy
  • Pre-treated HIV-infected patients
  • Salvage therapy

Fingerprint Dive into the research topics of 'Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen'. Together they form a unique fingerprint.

  • Cite this

    Burgos, J., Crespo, M., Falcó, V., Curran, A., Imaz, A., Domingo, P., Podzamczer, D., Mateo, M. G., Van den eynde, E., Villar, S., & Ribera, E. (2012). Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. Journal of Antimicrobial Chemotherapy, 67(6), 1453-1458. [dks057]. https://doi.org/10.1093/jac/dks057